Novel Targets for Development of Drugs for Treating Schizophrenia: Focus on Glycine, D-Serine and Nitric Oxide

被引:7
作者
Dhami, Kamaldeep [1 ]
MacKay, Marnie [1 ]
Maia-de-Oliveira, Joao Paulo [2 ]
Hallak, Jaime [1 ,2 ]
Todd, Kathryn [1 ]
Baker, Glen [1 ,2 ]
Dursun, Serdar [1 ,2 ]
机构
[1] Univ Alberta, Neurochem Res Unit, Dept Psychiat, Edmonton, AB T6G 2G3, Canada
[2] Ribeirao Preto Med Sch, Natl Inst Sci & Technol Translat Med, Sao Paulo, Brazil
来源
KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY | 2013年 / 23卷 / 02期
关键词
D-serine; dopamine; glutamate; glycine reuptake; nitric oxide; schizophrenia; sodium nitroprusside; NMDA RECEPTOR; CYCLIC-GMP; IN-VITRO; ANTIPSYCHOTIC EFFICACY; CEREBROSPINAL-FLUID; COGNITIVE DEFICITS; TRANSPORTER TYPE-1; MEDIATED RESPONSES; NEGATIVE SYMPTOMS; N-METHYLGLYCINE;
D O I
10.5455/bcp.20130629042437
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
For many years the focus of neurochemical and pharmacological studies on schizophrenia was on dopamine, and that work yielded a great deal of information about the possible etiology of this debilitating disorder and contributed significantly to the development of antipsychotic drugs. However, it has become increasingly apparent that other neurotransmitters and neuromodulators must also play an important role, and in recent years there has been considerable interest in these other compounds and the systems related to them in the search for developing drugs that are more effective and have fewer side effects than the antipsychotics currently available. This review deals with three of those neuro chemicals, namely glycine, D-serine and nitric oxide, and shows how an increased knowledge of them may be important in the future diagnosis and/or pharmacotherapy of schizophrenia.
引用
收藏
页码:129 / 137
页数:9
相关论文
共 88 条
[1]   In vitro and in vivo pharmacological profile of AS057278, a selective D-amino acid oxidase inhibitor with potential anti-psychotic properties [J].
Adage, Tiziana ;
Trillat, Anne-Cecile ;
Quattropani, Anna ;
Perrin, Dominique ;
Cavare, Laurent ;
Shaw, Jeffrey ;
Guerassimenko, Oxana ;
Giachetti, Claudio ;
Greco, Beatrice ;
Chumakov, Ilya ;
Halazy, Serge ;
Roach, Arthur ;
Zaratin, Paola .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 (03) :200-214
[2]   Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial [J].
Akhondzadeh, Shahin ;
Ghayyoumi, Raofeh ;
Rezaei, Farzin ;
Salehi, Bahman ;
Modabbernia, Amir-Hossein ;
Maroufi, Azad ;
Esfandiari, Gholam-Reza ;
Naderi, Mehrangiz ;
Ghebleh, Fariba ;
Tabrizi, Mina ;
Rezazadeh, Shams-Ali .
PSYCHOPHARMACOLOGY, 2011, 213 (04) :809-815
[3]  
[Anonymous], JAMA PSYCHIAT
[4]  
Balu DT, 2013, P NATL ACAD IN PRESS
[5]  
Baumeister Alan A, 2002, J Hist Neurosci, V11, P265, DOI 10.1076/jhin.11.3.265.10391
[6]   Modulation of striatal dopamine release in vitro by agonists of the glycineB site of NMDA receptors;: interaction with antipsychotics [J].
Bennett, S ;
Gronier, B .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 527 (1-3) :52-59
[7]   Nitric Oxide and Schizophrenia: Present Knowledge and Emerging Concepts of Therapy [J].
Bernstein, Hans-Gert ;
Keilhoff, Gerburg ;
Steiner, Johann ;
Dobrowolny, Henrik ;
Bogerts, Bernhard .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2011, 10 (07) :792-807
[8]  
Bird DC, 2001, PSYCHOPHARMACOLOGY, V155, P299
[9]   Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat [J].
Black, Mark D. ;
Varty, Geoffrey B. ;
Arad, Michal ;
Barak, Segev ;
De Levie, Amaya ;
Boulay, Denis ;
Pichat, Philippe ;
Griebel, Guy ;
Weiner, Ina .
PSYCHOPHARMACOLOGY, 2009, 202 (1-3) :385-396
[10]   NITRIC-OXIDE, A NOVEL NEURONAL MESSENGER [J].
BREDT, DS ;
SNYDER, SH .
NEURON, 1992, 8 (01) :3-11